Cargando…
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients and ongoing studies show efficacy of treatment depe...
Autores principales: | Kaumaya, Pravin T. P., Guo, Linlin, Overholser, Jay, Penichet, Manuel L., Bekaii-Saab, Tanios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553530/ https://www.ncbi.nlm.nih.gov/pubmed/33117602 http://dx.doi.org/10.1080/2162402X.2020.1818437 |
Ejemplares similares
-
A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx)
por: Guo, Linlin, et al.
Publicado: (2022) -
Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
por: Guo, Linlin, et al.
Publicado: (2022) -
Vaxxing to elimination: smallpox vaccines as tools to fight mpox
por: Titanji, Boghuma K., et al.
Publicado: (2023) -
Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022) -
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)
por: Overholser, Jay, et al.
Publicado: (2015)